|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Cash flows from operating activities | |
| Net loss | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| Depreciation and amortization of long-term assets | |
| Noncash lease expense | |
| Amortization of debt discount | |
| Stock-based compensation expense | |
| Noncash change in the fair value of assets and liabilities, net | |
| Acquisition of in-process research and development | |
| Loss on disposal of fixed assets | |
| Loss on lease termination | |
| Loss on sale of investment held at fair value | |
| Gain on dissolution of a variable interest entity | |
| Gain on settlement of pre-existing contract | |
| Impairment of intangible assets | |
| Gain on other investments | |
| Noncash change in the fair value of digital assets, net | |
| Loss on extinguishment of debt | |
| Unrealized foreign exchange (gain) | |
| Losses from investments in equity method investees, net of tax | |
| Issuance costs allocated to pre-funded warrants | |
| Noncash loss on sale of investment held at fair value | |
| Other income, net | |
| Changes in operating assets and liabilities: | |
| Prepaid expenses and other current assets | |
| Accounts payable | |
| Accrued liabilities | |
| Deferred revenue | |
| Net cash used in operating activities | |
| Cash flows from investing activities | |
| Proceeds from sale and maturities of securities carried at fair value | |
| Proceeds from sale of other investment held at fair value | |
| Cash received in acquisition of IntelGenx Corp. | |
| Cash received in acquisition of Beckley Psytech Limited | |
| Cash paid for securities carried at fair value | |
| Cash paid for investments | |
| Cash paid for digital assets | |
| Cash paid for Psilera asset acquisition | |
| Cash paid for short-term convertible notes receivable and warrant - related party | |
| Cash paid for short-term notes receivable - related party | |
| Cash paid for capitalized internal-use software development costs | |
| Cash paid for intangible asset | |
| Cash paid for property and equipment | |
| Net cash provided by (used in) investing activities | |
| Cash flows from financing activities | |
| Proceeds from equity offerings, net of commissions | |
| Proceeds from issuance of pre-funded warrants | |
| Cash paid for common stock and pre-funded warrant issuance costs | |
| Proceeds from conversion of convertible notes to common shares | |
| Proceeds from issuance of shares upon exercise of stock options | |
| Proceeds from debt financing | |
| Cash paid for debt financing costs | |
| Proceeds from other financing | |
| Cash paid for debt extinguishment | |
| Net cash provided by financing activities | |
| Effect of foreign exchange rate changes on cash | |
| Net decrease in cash, cash equivalents and restricted cash | |
| Cash, cash equivalents and restricted cash - beginning of the period | |
| Cash, cash equivalents and restricted cash - end of the period | |
| Supplemental disclosures: | |
| Cash paid for interest | |
| Cash paid for taxes | |
| Supplemental disclosures of noncash investing and financing information: | |
| Right of use asset obtained in exchange for operating lease liabilities | |
| Common stock issuance costs in accounts payable and accrued liabilities | |
| Noncash exchange of convertible promissory note modification | |
| Discharge of notes receivable | |
| Noncash consideration for acquisition of Beckley Psytech | |
| Noncash transaction costs for services rendered to Beckley Psytech | |
| Noncash consideration for variable interest deconsolidation |
Loading...
